arrow
M

Martin Sebastian

Goethe University Frankfurt
H指数:41
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Visual extraction of individual patient data from published kaplan-meier survival plots using a web-based application offering different reconstruction methods (V-Exploder)

使用基于Web的应用程序(V-Exploder)及不同的重建方法从已发布的Kaplan-Meier生存曲线图中提取个体患者数据

2026-10-050
OAAI
Real-World First-Line Treatment Characteristics and Physician Drivers in Advanced/Metastatic Non–Small Cell Lung Cancer, PD-L1 ≥ 50%, and without Actionable Genomic Alterations

真实世界中PD-L1≥50%且无可操作基因组改变晚期/转移性非小细胞肺癌的一线治疗特征及医师驱动因素

2026-10-030
OA
Durvalumab Consolidation After Definitive Chemoradiotherapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer: A Real-World Cohort Analysis from the German Prospective, Observational CRISP Registry (AIO-TRK-0315)

不可切除III期非小细胞肺癌患者行根治性放化疗后的度鲁特单抗巩固治疗:来自德国前瞻性、观察性CRISP登记研究(AIO-TRK-0315)的真实世界队列分析

Cancers
IF4.4
2026-08-170
OAAI
Prediction of the individual risk for the development of brain metastases in patients with non-oncogene-addicted non-small cell lung cancer: Real-world data from the German prospective CRISP registry (AIO-TRK-0315)

预测非癌基因成瘾非小细胞肺癌患者发生脑转移的个体风险:来自德国前瞻性CRISP登记研究(AIO-TRK-0315)的真实世界数据

2026-03-010
OAAI
Feasibility and safety of nintedanib in combination with nivolumab in pretreated patients with advanced or metastatic adenocarcinoma of the lung – An AIO phase Ib/II trial

尼达尼布联合纳武利尤单抗在经治晚期或转移性肺腺癌患者中的可行性与安全性——一项AIO Ib/II期临床试验

2026-02-120
PRE
Institutional Variability in Testing for Actionable Genetic Alterations in Patients with Stage IIIB/C or IV Non-Small Cell Lung Cancer: A Real-World Study from the German Prospective, Observational, Multicenter CRISP Registry (AIO-TRK-0315)

IIIB/C或IV期非小细胞肺癌患者可行遗传改变测试的机构变异性: 来自德国前瞻性,观察性,多中心CRISP注册中心 (AIO-TRK-0315) 的一项真实研究

2026-01-300
PRE
Study design and rationale for the NeoTRACE trial: a multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer

NeoTRACE试验的研究设计与原理:一项多中心II期研究,评估新辅助沙库巴曲舒坦联合吉米单抗,随后进行辅助吉米单抗联合或不联合沙库巴曲舒坦在可切除非小细胞肺癌患者中的应用。

2025-11-210
PRE
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity

长期接受帕博利珠单抗单药治疗的患者中,具有晚期非小细胞肺癌、PD-L1表达≥50%且体力状况较差者的长期结局:基于Transformer的AI用于表征预后复杂性

2025-10-160
OAAI
Treatment Sequences in BRAF-V600–Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy

BRAF-V600-Mutated NSCLC的治疗顺序: 一线靶向治疗与一线 (化疗) 免疫治疗

2025-05-080
OAAI
Status epilepticus in patients with brain tumors and metastases: A multicenter cohort study of 208 patients and literature review
2024-04-044
OAAI
Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)
2024-04-011
OA
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany

Sotorasib在KRAS G12C-mutated非小细胞肺癌: 来自德国同情使用计划的多中心现实世界经验

2024-04-018
OA
Patient-reported outcomes in advanced NSCLC before and during the COVID-19 pandemic: Real-world data from the German prospective CRISP Registry (AIO-TRK-0315)
2024-02-080
OAAI
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancerdfinal results of the EUCROSS trial
2024-02-011
OAAI